Pamoic acid disodium

Research use only, not for human use.

Pamoic acid disodium is a GPR35 agonist.

Pamoic acid disodium is a potent GPR35 agonist with an EC50 value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates ERK1/2 with EC50 values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect.

Western Blot AnalysisCell Line:U2OS cells Concentration:1, 10, 100 nM and 1, 10 μM Incubation Time:15 min Result:A concentration-dependent activation of ERK1/2 was observed with an EC50 of 65 nM.

Animal Model:Swiss-Webster mice (30–35 g)Dosage:25, 50, and 100 mg/kg Administration:Subcutaneous injection, once Result:Elicited dose-related antinociception, the dose causing 50% antinociception being 40.5 mg/kg.

——

Others

Other Targets

Others

——

——

6640-22-8

411.36

C23H16NaO6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (231.30 mM; Ultrasonic (<60°C)

[Na+].[Na+].Oc1c(cc2ccccc2c1Cc1c(O)c(cc2ccccc12)C([O-])=O)C([O-])=O

——

(-20℃)

With Ice Pack

≥ 2 years